Back to results

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Primary Purpose

Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer

Status

Recruiting

Phase

Phase 1

Locations

International

Study Type

Interventional

Intervention

STRO-002

About this trial

This is an interventional treatment trial for Ovarian Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

Age ≥ 18 years
Measurable disease per RECIST 1.1
ECOG performance status (0-1)
Life expectancy > 3 months
Pathological confirmation of disease under study (historical information, diagnosis, pathology report, etc)
1. Expansion Cohort A: High-grade serous EOC, fallopian tube cancer or primary peritoneal cancer
2. Expansion Cohort B: Histologically diagnosed epithelial endometrial cancer (endometrioid and serous adenocarcinomas; undifferentiated carcinoma; mixed epithelial carcinoma; or adenocarcinoma NOS)
Relapsed and/or progressive disease
1. Dose Expansion Cohort A (Ovarian Cancer):
  - Platinum resistant and received 1-3 prior regimens or
  - Platinum sensitive and either:
  - Progressed after 2 prior lines of platinum therapy (regardless of platinum status)and received 2-3 prior regimens or
  - Progressed after 1 line of platinum therapy and 1 line of non-platinum therapy and received a total of 2-3 prior regimens if contraindicated to receive second platinum regimen.
2. Dose Expansion Cohort B (Endometrial Cancer):
  - Relapsed or progression after at least 1 platinum-based chemotherapy regimen or 1 immunotherapy-based regimen but not to exceed more than 3 prior regimens.
Fresh or archival tumor tissue samples

Exclusion Criteria:

Low grade (grade 1) ovarian carcinoma, clear cell, mucinous and sarcomatous ovarian carcinomas (Cohort A).
Endometrial carcinosarcomas, leiomyosarcoma and stromal sarcomas (Cohort B).
Prior treatment with a FolRα-targeting ADCs or FolRα-targeting vaccines
Platinum-refractory during frontline treatment (Cohort A)
Greater than 3 lines of prior treatment
History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment
Preexisting clinically significant ocular disorders, clinically significant pre-exisiting ocular disorders, severe chronic obstructive pulmonary disease or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition
Metastatic central nervous system or meningeal disease
Concurrent participation in another therapeutic treatment trial

Sites / Locations

Arizona Oncology - TucsonRecruiting
UCLA Jonsson Comprehensive Cancer Center Clinical Research UnitRecruiting
Sutter Health- Palo Alto Medical FoundationRecruiting
Rocky Mountain Cancer CenterRecruiting
Yale School of MedicineRecruiting
Miami Cancer Institue, Baptist Health South FloridaRecruiting
University of South FloridaRecruiting
Augusta OncologyRecruiting
University of ChicagoRecruiting
Maryland Oncology HematologyRecruiting
Minnesota Oncology HematologyRecruiting
Comprehensive Cancer Centers of NevadaRecruiting
NYU Langone Medical CenterRecruiting
Levine Cancer InstituteRecruiting
University of Cincinnati Cancer InstituteRecruiting
Ohio State University, James Cancer CenterRecruiting
University of PennsylvaniaRecruiting
Thomas Jefferson UniversityRecruiting
Prisma HealthRecruiting
Sarah Cannon Research InstituteRecruiting
Virginia Cancer SpecialistsRecruiting
Cancer Care Northwest-South SpokaneRecruiting
Medical College of WisconsinRecruiting
Vall d'Hebron Institut d'OncologiaRecruiting
Clínica Universidad de Navarra -MadridRecruiting
Hospital Universitario La PazRecruiting
Hospital Universitario HM Sanchinarro - CIOCCRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

STRO-002 treatment

Arm Description

Dose Escalation: STRO-002 at increasing dose levels Dose Expansion: STRO-002 at 4.3 mg/kg and 5.2 mg/kg

Outcomes

Primary Outcome Measures

Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)

Incidence of adverse events (AEs) observed across STRO-002 dose levels

Part 1: Define the recommended phase 2 dose (RP2D) of STRO-002

Frequency of dose-limiting toxicity and exposure across STRO-002 dose levels

Part 1: Define the maximum tolerated dose (MTD) of STRO-002

Frequency of dose-limiting toxicity and exposure across STRO-002 dose levels

Part 2: Evaluate preliminary anti-tumor activity (ovarian, Fallopian and primary peritoneal cancer patients)

Objective response rate per RECIST 1.1

Part 2: Evaluate preliminary anti-tumor activity (endometrial cancer patients)

Objective response rate per RECIST 1.1

Secondary Outcome Measures

Part 1: Characterize the pharmacokinetics (PK) of STRO-002 by measuring the maximum plasma concentration (Cmax)

Measurement of maximum plasma concentration after the administration of STRO-002

Part 1: Characterize the PK of STRO-002 by measuring the half-life (t1/2) of STRO-002

Measurement of terminal half-life of STRO-002 after the administration of STRO-002

Part 1: Characterize the PK of STRO-002 measuring the total area under the concentration versus time curve from zero to infinity (AUCinf)

Measurement of AUC to infinity (AUCinf)

Part 1: Characterize the PK of STRO-002 by measuring the clearance (CL)

Measurement of total body clearance

Part 1: Characterize the PK of STRO-002 by measuring the the steady state volume of distribution (Vss)

Measurement of steady state volume of distribution

Part 1: Assess the formulation of anti-drug antibodies to STRO-002

Circulating anti-drug antibodies (ADAs) formed to STRO-002

Part 2: Further evaluate the incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)

Number of patients with abnormal laboratory values and/or adverse events related to STRO-002 treatment

Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of duration of response (DOR) in patients treated with STRO-002

Duration of response per RECIST 1.1

Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of progression-free survival (PFS) in patients treated with STRO-002

Progression-free survival per RECIST 1.1

Part 2: Evaluate preliminary effect of STRO-002 treatment on CA-125 levels

Response assessment based on the Gynecologic Cancer Intergroup (GCIG) criteria

Part 2: Characterize the PK of STRO-002 by measuring the maximum plasma concentration (Cmax)

Measurement of maximum plasma concentration (Cmax) after the administration of STRO-002

Part 2: Characterize the PK of STRO-002 by measuring the area under the plasma concentration versus time curve (AUC)

Measurement of AUC to infinity (AUC inf)

Part 2: Characterize the PK of STRO-002 by measuring the clearance (CL)

Measurement of total body clearance

Full Information

NCT ID

NCT03748186

First Posted

November 13, 2018

Last Updated

February 7, 2023

Sponsor

Sutro Biopharma, Inc.

1. Study Identification

Unique Protocol Identification Number

NCT03748186

Brief Title

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

Official Title

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers

Study Type

Interventional

2. Study Status

Record Verification Date

February 2023

Overall Recruitment Status

Recruiting

Study Start Date

February 1, 2019 (Actual)

Primary Completion Date

August 2024 (Anticipated)

Study Completion Date

August 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Sutro Biopharma, Inc.

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.

Detailed Description

This study is a phase 1, open-label, multicenter, dose-escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D) and to evaluate the safety, tolerability, and preliminary antitumor activity of STRO-002 in adult subjects with advanced epithelial ovarian cancer (EOC), including fallopian or primary peritoneal cancer, and endometrial cancer. Fallopian tube and primary peritoneal cancers are treated in the same manner as epithelial ovarian cancers and are thus included in this phase 1 study. Subjects enrolled in the study will be required to have progressive or recurrent disease after standard approved therapy as defined in the study eligibility criteria. The study has completed dose escalation and is currently in dose expansion, enrolling endometrial and ovarian cancer subjects. All subjects enrolled on the study are required to have tumor tissue for determining folate receptor alpha (FolRα) expression levels, either from a prior surgery or tumor biopsy or from a biopsy performed during study screening. The testing for FolRα is done via an ICH assay. A minimum level of FolRα expression is required for enrollment for endometrial cancer but not for ovarian cancer. Study drug, STRO-002, is administered by intravenous (IV) infusion on day 1 of 21-day cycles. Clinical evaluations and/or laboratory tests will be performed at a pre-specified schedule-weekly for cycles 1-4, and at the beginning of every cycle starting with cycle 5 as described in the schedule of assessments. Samples for PK analysis will occur at specific times on days 1, 8, and 15 of cycles 1 and 4, Day 1 of cycles 2, 3, and 5 and at the end of treatment (EOT) visit. The study requires imaging with a CT or MRI scan of the chest abdomen and pelvis at screening, every 6 weeks after enrollment for the first 18 weeks, then every 9 weeks, and at the end of treatment (EOT) visit. Additional X-rays may be required to confirm disease responses and per local institution standard of care. Additional clinical evaluations and lab testing may occur at the discretion of the investigator.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 1

Interventional Study Model

Sequential Assignment

Model Description

The study is a modified 3+3 dose escalation study with a dose expansion. Dose escalation is in advanced ovarian cancer patients with relapsed or refractory disease to standard approved therapy. Dose expansion includes 2 cancer populations, ovarian cancer and endometrial cancer. The ovarian cancer expansion cohorts are Cohort A and Cohort C. Cohort A is a dose ranging design with randomization into 2 dose levels of STRO-002, 4.3 mg/kg and 5.2mg/kg. Cohort C is a single dose cohort design, STRO-002 5.2 mg/kg with prophylactic pegfilgrastim. Dose expansion in endometrial cancer (Cohort B) is a single dose cohort design, STRO-002 5.2 mg/kg. Endometrial subjects with prior pelvic irradiation will start treatment of STRO-002 at 4.3 mg/kg with step up to 5.2 mg/kg.

Masking

None (Open Label)

Allocation

N/A

Enrollment

160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title

STRO-002 treatment

Arm Type

Experimental

Arm Description

Dose Escalation: STRO-002 at increasing dose levels Dose Expansion: STRO-002 at 4.3 mg/kg and 5.2 mg/kg

Intervention Type

Drug

Intervention Name(s)

STRO-002

Intervention Description

intravenous antibody drug conjugate

Primary Outcome Measure Information:

Title

Part 1: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)

Description

Incidence of adverse events (AEs) observed across STRO-002 dose levels

Time Frame

18 months

Title

Part 1: Define the recommended phase 2 dose (RP2D) of STRO-002

Description

Frequency of dose-limiting toxicity and exposure across STRO-002 dose levels

Time Frame

18 months

Title

Part 1: Define the maximum tolerated dose (MTD) of STRO-002

Description

Frequency of dose-limiting toxicity and exposure across STRO-002 dose levels

Time Frame

18 months

Title

Part 2: Evaluate preliminary anti-tumor activity (ovarian, Fallopian and primary peritoneal cancer patients)

Description

Objective response rate per RECIST 1.1

Time Frame

24 months

Title

Part 2: Evaluate preliminary anti-tumor activity (endometrial cancer patients)

Description

Objective response rate per RECIST 1.1

Time Frame

24 months

Secondary Outcome Measure Information:

Title

Part 1: Characterize the pharmacokinetics (PK) of STRO-002 by measuring the maximum plasma concentration (Cmax)

Description

Measurement of maximum plasma concentration after the administration of STRO-002

Time Frame

18 months

Title

Part 1: Characterize the PK of STRO-002 by measuring the half-life (t1/2) of STRO-002

Description

Measurement of terminal half-life of STRO-002 after the administration of STRO-002

Time Frame

18 months

Title

Part 1: Characterize the PK of STRO-002 measuring the total area under the concentration versus time curve from zero to infinity (AUCinf)

Description

Measurement of AUC to infinity (AUCinf)

Time Frame

18 months

Title

Part 1: Characterize the PK of STRO-002 by measuring the clearance (CL)

Description

Measurement of total body clearance

Time Frame

18 months

Title

Part 1: Characterize the PK of STRO-002 by measuring the the steady state volume of distribution (Vss)

Description

Measurement of steady state volume of distribution

Time Frame

18 months

Title

Part 1: Assess the formulation of anti-drug antibodies to STRO-002

Description

Circulating anti-drug antibodies (ADAs) formed to STRO-002

Time Frame

18 months

Title

Part 2: Further evaluate the incidence of Treatment-Emergent Adverse Events (Safety and Tolerability of STRO-002)

Description

Number of patients with abnormal laboratory values and/or adverse events related to STRO-002 treatment

Time Frame

24 months

Title

Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of duration of response (DOR) in patients treated with STRO-002

Description

Duration of response per RECIST 1.1

Time Frame

24 months

Title

Part 2: Evaluate preliminary anti-tumor efficacy with a time-to-event analysis of progression-free survival (PFS) in patients treated with STRO-002

Description

Progression-free survival per RECIST 1.1

Time Frame

24 months

Title

Part 2: Evaluate preliminary effect of STRO-002 treatment on CA-125 levels

Description

Response assessment based on the Gynecologic Cancer Intergroup (GCIG) criteria

Time Frame

24 months

Title

Part 2: Characterize the PK of STRO-002 by measuring the maximum plasma concentration (Cmax)

Description

Measurement of maximum plasma concentration (Cmax) after the administration of STRO-002

Time Frame

24 months

Title

Part 2: Characterize the PK of STRO-002 by measuring the area under the plasma concentration versus time curve (AUC)

Description

Measurement of AUC to infinity (AUC inf)

Time Frame

24 months

Title

Part 2: Characterize the PK of STRO-002 by measuring the clearance (CL)

Description

Measurement of total body clearance

Time Frame

24 months

Other Pre-specified Outcome Measures:

Title

Part 1: Preliminary assessment of the anti-tumor activity of STRO-002

Description

Objective response rate per RECIST 1.1

Time Frame

18 months

10. Eligibility

Sex

Female

Gender Based

Yes

Gender Eligibility Description

Patients are required to have ovarian, fallopian, primary peritoneal or endometrial cancer.

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Age ≥ 18 years Measurable disease per RECIST 1.1 ECOG performance status (0-1) Life expectancy > 3 months Pathological confirmation of disease under study (historical information, diagnosis, pathology report, etc) Expansion Cohorts A and C: High-grade serous EOC, fallopian tube cancer or primary peritoneal cancer Expansion Cohort B: Histologically diagnosed epithelial endometrial cancer (endometrioid and serous adenocarcinomas; undifferentiated carcinoma; mixed epithelial carcinoma; or adenocarcinoma NOS) Relapsed and/or progressive disease Dose Expansion Cohorts A and C (Ovarian Cancer): Platinum resistant and received 1-3 prior regimens or Platinum sensitive and either: Progressed after 2 prior lines of platinum therapy (regardless of platinum status)and received 2-3 prior regimens or Progressed after 1 line of platinum therapy and 1 line of non-platinum therapy and received a total of 2-3 prior regimens if contraindicated to receive second platinum regimen. Dose Expansion Cohort B (Endometrial Cancer): Relapsed or progression after at least 1 platinum-based chemotherapy regimen or 1 immunotherapy-based regimen but not to exceed more than 3 prior regimens. Fresh or archival tumor tissue samples Exclusion Criteria: Low grade (grade 1) ovarian carcinoma, clear cell, mucinous and sarcomatous ovarian carcinomas (Cohort A). Endometrial carcinosarcomas, leiomyosarcoma and stromal sarcomas (Cohort B). Prior treatment with a FolRα-targeting ADCs or FolRα-targeting vaccines Platinum-refractory during frontline treatment (Cohorts A and C) Greater than 3 lines of prior treatment History of severe allergic or anaphylactic reactions to monoclonal antibody therapy or to antibody-related fusion protein treatment Preexisting clinically significant ocular disorders, clinically significant pre-exisiting ocular disorders, severe chronic obstructive pulmonary disease or asthma, clinically significant cardiac or cerebrovascular disease, or other significant concurrent, uncontrolled medical condition Metastatic central nervous system or meningeal disease Concurrent participation in another therapeutic treatment trial

Central Contact Person:

First Name & Middle Initial & Last Name or Official Title & Degree

Craig Berman, MD

Phone

650-801-6417

STRO-002ClinDev@sutrobio.com

First Name & Middle Initial & Last Name or Official Title & Degree

Michael Palumbo

Phone

650-676-4689

STRO-002ClinDev@sutrobio.com

Facility Information:

Facility Name

Arizona Oncology - Tucson

City

Tucson

State/Province

Arizona

ZIP/Postal Code

85711

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Julie Klinker

Phone

520-269-3821

julie.klinker@usoncology.com

First Name & Middle Initial & Last Name & Degree

Joseph Buscema, MD

Facility Name

UCLA Jonsson Comprehensive Cancer Center Clinical Research Unit

City

Los Angeles

State/Province

California

ZIP/Postal Code

90095

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Kimberly Kelly

Phone

310-206-8309

KMKelly@mednet.ucla.edu

First Name & Middle Initial & Last Name & Degree

Anurit Dhillon

Phone

310-825-7028

AKDhillon@mednet.ucla.edu

First Name & Middle Initial & Last Name & Degree

Gottfried Konecny, MD

Facility Name

Sutter Health- Palo Alto Medical Foundation

City

San Francisco

State/Province

California

ZIP/Postal Code

94109

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Irene Li

Phone

415-600-5848

Irene.Li@sutterhealth.org

First Name & Middle Initial & Last Name & Degree

Chris Argueta

Phone

415-600-5848

arguec1@sutterhealth.org

First Name & Middle Initial & Last Name & Degree

John Chan, MD

Facility Name

Rocky Mountain Cancer Center

City

Aurora

State/Province

Colorado

ZIP/Postal Code

80012

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Patty Gibson, RN, BSN

Phone

303-418-7639

Patricia.Gibson@usoncology.com

First Name & Middle Initial & Last Name & Degree

Sami Diab, MD

First Name & Middle Initial & Last Name & Degree

Manojkumar Bupathi, MD

Facility Name

Yale School of Medicine

City

New Haven

State/Province

Connecticut

ZIP/Postal Code

06520

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Lisa Baker, RN, BSN, OCN

Phone

203-785-6398

lisa.baker@yale.edu

First Name & Middle Initial & Last Name & Degree

Martha Luther

Phone

203-737-2781

martha.luther@yale.edu

First Name & Middle Initial & Last Name & Degree

Alessandro Santin, MD

Facility Name

Miami Cancer Institue, Baptist Health South Florida

City

Miami

State/Province

Florida

ZIP/Postal Code

33176

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Isabel Moya, BSCR, CCRP

Phone

786-527-8861

IsabelMoy@baptisthealth.net

First Name & Middle Initial & Last Name & Degree

John Diaz, MD

Facility Name

University of South Florida

City

Tampa

State/Province

Florida

ZIP/Postal Code

33606

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Matthew Anderson

Phone

813-974-1806

mlander5@usf.edu

First Name & Middle Initial & Last Name & Degree

Matthew Anderson, MD

Facility Name

Augusta Oncology

City

Augusta

State/Province

Georgia

ZIP/Postal Code

30912

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Melissa James

Phone

706-721-8981

mejames@augusta.edu

First Name & Middle Initial & Last Name & Degree

Sharad Ghamande, MD

Facility Name

University of Chicago

City

Chicago

State/Province

Illinois

ZIP/Postal Code

60637

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Hatti Koning

Phone

773-834-5722

hkoning@medicine.bsd.uchicago.edu

First Name & Middle Initial & Last Name & Degree

John Moroney, MD

Facility Name

Maryland Oncology Hematology

City

Rockville

State/Province

Maryland

ZIP/Postal Code

20850

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Missy Almand

Phone

877-664-7724

missy.almand@usoncology.com

First Name & Middle Initial & Last Name & Degree

Cheryl Aylesworth, MD

Facility Name

Minnesota Oncology Hematology

City

Minneapolis

State/Province

Minnesota

ZIP/Postal Code

55404

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Lynn Anderson

Phone

612-884-6331

lynn.anderson@usoncology.com

First Name & Middle Initial & Last Name & Degree

Emily Prendergast, MD

Facility Name

Comprehensive Cancer Centers of Nevada

City

Las Vegas

State/Province

Nevada

ZIP/Postal Code

89169

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Karyn Mianulli, BSN, RN

Phone

702-952-3443

karyn.mianulli@usoncology.com

First Name & Middle Initial & Last Name & Degree

Fadi Braiteh, MD

Facility Name

NYU Langone Medical Center

City

New York

State/Province

New York

ZIP/Postal Code

10016

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Priyanka Patel

Priyanka.Patel@nyulangone.org

First Name & Middle Initial & Last Name & Degree

Alison Haegler

Alison.Haegler@nyulangone.org

First Name & Middle Initial & Last Name & Degree

Bhavana Pothuri, MD

Facility Name

Levine Cancer Institute

City

Charlotte

State/Province

North Carolina

ZIP/Postal Code

28204

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Heather Neagle, RN, BSN

Phone

980-442-2303

Heather.Neagle@atriumhealth.org

First Name & Middle Initial & Last Name & Degree

R. Wendel Naumann, MD

Facility Name

University of Cincinnati Cancer Institute

City

Cincinnati

State/Province

Ohio

ZIP/Postal Code

45267

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Christine Vollmer

Phone

513-584-7698

cancer@uchealth.com

First Name & Middle Initial & Last Name & Degree

Amanda Jackson, MD

Facility Name

Ohio State University, James Cancer Center

City

Columbus

State/Province

Ohio

ZIP/Postal Code

43210

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Molly Myers

Phone

614-293-3873

Molly.Myers@osumc.edu

First Name & Middle Initial & Last Name & Degree

David O'Malley, MD

Facility Name

University of Pennsylvania

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19104

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Diego Rodgriguez

Phone

215-614-0234

diegorod@pennmedicine.upenn.edu

First Name & Middle Initial & Last Name & Degree

Lainie Martin, MD

Facility Name

Thomas Jefferson University

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19107

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Cynthia Perez, BS, CCRP

Phone

215-955-6407

cynthia.perez@jefferson.edu

First Name & Middle Initial & Last Name & Degree

Russell Schilder, MD

Facility Name

Prisma Health

City

Greenville

State/Province

South Carolina

ZIP/Postal Code

29605

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Jan Kueber

Phone

864-455-3774

jan.kueber@prismahealth.org

First Name & Middle Initial & Last Name & Degree

Jeff Edenfield, MD

Facility Name

Sarah Cannon Research Institute

City

Nashville

State/Province

Tennessee

ZIP/Postal Code

37203

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Sheetal Champaneria

Phone

615-329-6875

sheetal.champaneria@sarahcannon.com

First Name & Middle Initial & Last Name & Degree

Erika Hamilton, MD

Facility Name

Virginia Cancer Specialists

City

Fairfax

State/Province

Virginia

ZIP/Postal Code

22031

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Marcy Sullivan

Phone

703-208-9268

Marcy.Sullivan@usoncology.com

First Name & Middle Initial & Last Name & Degree

Alexander Spira, MD

Facility Name

Cancer Care Northwest-South Spokane

City

Spokane

State/Province

Washington

ZIP/Postal Code

99204

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Carissa Urbat

Phone

509-474-3820

Lisa.davis2@providence.org

First Name & Middle Initial & Last Name & Degree

Melanie Bergman, MD

Facility Name

Medical College of Wisconsin

City

Milwaukee

State/Province

Wisconsin

ZIP/Postal Code

53226

Country

United States

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Suki Skandarajah

Phone

414-805-5337

sskandarajah@mcw.edu

First Name & Middle Initial & Last Name & Degree

Denise Uyar, MD

Facility Name

Vall d'Hebron Institut d'Oncologia

City

Barcelona

ZIP/Postal Code

08035

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Nuria Farras Llansana

Phone

(+34)93-489-4158

nfarras@vhio.net

First Name & Middle Initial & Last Name & Degree

Ana Oaknin Benzaquen, MD

Facility Name

Clínica Universidad de Navarra -Madrid

City

Madrid

ZIP/Postal Code

28027

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Antonio Gonzalez Martin, MD

Phone

+34913531920

agonzalezma@unav.es

First Name & Middle Initial & Last Name & Degree

Eduardo Castañón, MD

Phone

+34913531920

ecastanon@unav.es

First Name & Middle Initial & Last Name & Degree

Antonio Gonzalez Martin

Facility Name

Hospital Universitario La Paz

City

Madrid

ZIP/Postal Code

28046

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Yolanda Alvarez

Phone

+34 91 727 75 16

yolandalapaz@gmail.com

First Name & Middle Initial & Last Name & Degree

Andres Redondo Sanchez, MD

Facility Name

Hospital Universitario HM Sanchinarro - CIOCC

City

Madrid

ZIP/Postal Code

28050

Country

Spain

Individual Site Status

Recruiting

Facility Contact:

First Name & Middle Initial & Last Name & Degree

Patricia Morgades

Phone

+34 91 756 79 84

Ext

4887

pmorgades@hmhospitales.com

First Name & Middle Initial & Last Name & Degree

Jesus Garcia-Donas, MD

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

We'll reach out to this number within 24 hrs